Spectrascience New Net Worth

Spectrascience New Net Worth Breakdown

  SCIE
The net worth of Spectrascience New is the difference between its total assets and liabilities. Spectrascience New's net worth represents the value of the company's equity or ownership interest. In other words, it is the amount of money that would be left over if all of Spectrascience New's assets were sold and all of its debts were paid off. Net worth is sometimes referred to as shareholder's equity or book value. Spectrascience New's net worth can be used as a measure of its financial health and stability which can help investors to decide if Spectrascience New is a good investment. It is also essential in determining the company's creditworthiness and ability to secure financing before investing in Spectrascience New stock.

Spectrascience New Net Worth Analysis

Spectrascience New's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Spectrascience New's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Spectrascience New's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Spectrascience New's net worth analysis. One common approach is to calculate Spectrascience New's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Spectrascience New's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Spectrascience New's net worth. This approach calculates the present value of Spectrascience New's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Spectrascience New's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Spectrascience New's net worth. This involves comparing Spectrascience New's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Spectrascience New's net worth relative to its peers.

Enterprise Value

9.47 Million

To determine if Spectrascience New is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Spectrascience New's net worth research are outlined below:
Spectrascience New generated a negative expected return over the last 90 days
Spectrascience New has some characteristics of a very speculative penny stock
Spectrascience New has high likelihood to experience some financial distress in the next 2 years
Spectrascience New currently holds 6.38 M in liabilities. Spectrascience New has a current ratio of 0.02, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Spectrascience New's use of debt, we should always consider it together with its cash and equity.
The entity reported the previous year's revenue of 5.15 K. Net Loss for the year was (4.47 M) with loss before overhead, payroll, taxes, and interest of (196.44 K).
Spectrascience New currently holds about 27.88 K in cash with (1.51 M) of positive cash flow from operations.
Spectrascience New has a frail financial position based on the latest SEC disclosures

Follow Spectrascience New's market capitalization trends

The company currently falls under 'Nano-Cap' category with a current market capitalization of 4.92 K.

Market Cap

1.3 Million

Project Spectrascience New's profitablity

Last ReportedProjected for Next Year
Return On Tangible Assets(14.20)(13.49)
Return On Capital Employed 0.23  0.25 
Return On Assets(3.71)(3.52)
Return On Equity 0.38  0.40 
When accessing Spectrascience New's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Spectrascience New's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Spectrascience New's profitability and make more informed investment decisions.
Please note, the presentation of Spectrascience New's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Spectrascience New's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Spectrascience New's management manipulating its earnings.

Evaluate Spectrascience New's management efficiency

Spectrascience New has return on total asset (ROA) of (0.9247) % which means that it has lost $0.9247 on every $100 spent on assets. This is way below average. Spectrascience New's management efficiency ratios could be used to measure how well Spectrascience New manages its routine affairs as well as how well it operates its assets and liabilities. At present, Spectrascience New's Return On Equity is projected to slightly decrease based on the last few years of reporting. At present, Spectrascience New's Total Current Assets are projected to decrease significantly based on the last few years of reporting. The current year's Debt To Assets is expected to grow to 5.10, whereas Other Assets are forecasted to decline to about 88.4 K.
Last ReportedProjected for Next Year
Book Value Per Share(0.02)(0.02)
Tangible Book Value Per Share(0.02)(0.02)
Enterprise Value Over EBITDA(3.16)(3.01)
Price Book Value Ratio(0.13)(0.12)
Enterprise Value Multiple(3.16)(3.01)
Price Fair Value(0.13)(0.12)
Enterprise Value10 M9.5 M
The operational strategies employed by Spectrascience New management play a crucial role in its market positioning. Assessing these strategies alongside financial data helps us evaluate the stock's investment potential.
Enterprise Value Revenue
K
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Spectrascience New insiders, such as employees or executives, is commonly permitted as long as it does not rely on Spectrascience New's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Spectrascience New insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Spectrascience New Earnings per Share Projection vs Actual

Spectrascience New Corporate Executives

Elected by the shareholders, the Spectrascience New's board of directors comprises two types of representatives: Spectrascience New inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Spectrascience. The board's role is to monitor Spectrascience New's management team and ensure that shareholders' interests are well served. Spectrascience New's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Spectrascience New's outside directors are responsible for providing unbiased perspectives on the board's policies.
Lowell GiffhornCFO, Principal Accounting Officer and SecretaryProfile
When determining whether Spectrascience New is a strong investment it is important to analyze Spectrascience New's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Spectrascience New's future performance. For an informed investment choice regarding Spectrascience Stock, refer to the following important reports:
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Spectrascience New. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
For information on how to trade Spectrascience Stock refer to our How to Trade Spectrascience Stock guide.
You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Spectrascience New. If investors know Spectrascience will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Spectrascience New listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.01)
Return On Assets
(0.92)
The market value of Spectrascience New is measured differently than its book value, which is the value of Spectrascience that is recorded on the company's balance sheet. Investors also form their own opinion of Spectrascience New's value that differs from its market value or its book value, called intrinsic value, which is Spectrascience New's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Spectrascience New's market value can be influenced by many factors that don't directly affect Spectrascience New's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Spectrascience New's value and its price as these two are different measures arrived at by different means. Investors typically determine if Spectrascience New is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Spectrascience New's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.